Form 4: Pfizer CEO Acquires Phantom Stock Units

Pfizer Inc.'s Chairman and CEO, Albert Bourla, acquired 24 phantom stock units on November 14, 2025, increasing his beneficial ownership to 743,548 units.

Summary

• Albert Bourla, Chairman and CEO of Pfizer Inc., acquired 24 phantom stock units.
• The transaction occurred on November 14, 2025.
• Each unit represents one phantom share of common stock, valued at $25.06.
• Following this acquisition, Bourla beneficially owns a total of 743,548 phantom stock units.
• These units were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan.
• The phantom stock units are settled in cash upon the reporting person's separation from service and can be transferred into an alternative investment account at any time.

Sentiment

Score: 7

Explanation: The acquisition of phantom stock units by the Chairman and CEO, while a routine compensation event, generally signals continued executive alignment and confidence in the company's long-term prospects, contributing to a moderately positive sentiment.

Positives

• Chairman and CEO Albert Bourla increased his beneficial ownership in Pfizer Inc. through the acquisition of phantom stock units.
• The acquisition of additional units by a key executive may signal continued confidence in the company's future performance and long-term strategy.

Negatives

• NA

Risks

• NA

Future Outlook

NA

Management Comments

• NA

Industry Context

This filing reflects a routine executive compensation activity within the pharmaceutical industry, where deferred compensation plans often include equity-linked instruments like phantom stock units. Such plans are designed to align executive interests with shareholder value over the long term by tying compensation to the company's stock performance.

Comparison to Industry Standards

• The use of phantom stock units as a component of executive compensation is a common practice across large-cap pharmaceutical companies and other industries, serving to align executive incentives with company performance without immediate equity dilution.
• The structure, where units are settled in cash upon separation from service, is typical for non-funded deferred compensation plans, offering tax deferral benefits to the executive while linking their long-term wealth to the company's stock performance.

Management Changes

Corporate Governance

Legal Proceedings

• NA

Related Party Transactions

• The acquisition of phantom stock units by Chairman and CEO Albert Bourla from Pfizer Inc. is a related party transaction, as it is part of his executive compensation package and involves the company and a key executive.

Stakeholder Impact

• Shareholders: The transaction, being part of a deferred compensation plan, aligns executive interests with long-term shareholder value, as the units are tied to the company's common stock performance.
• Employees: This filing pertains specifically to executive compensation and does not directly impact the broader employee base.

Next Steps

• NA

Key Dates

Recommendation

This Form 4 reports a routine acquisition of phantom stock units by the CEO as part of a deferred compensation plan. While it indicates continued executive alignment, the transaction size and nature are not significant enough to warrant a change in investment recommendation based solely on this filing. The overall investment thesis for Pfizer Inc. remains dependent on broader financial performance, pipeline developments, and market conditions.

Keywords

Pfizer, PFE, Albert Bourla, insider transaction, Form 4, phantom stock units, executive compensation, deferred compensation